CYFENDUS is developed by Emergent BioSolutions.

What development phase is CYFENDUS in?

CYFENDUS is FDA-approved (marketed).

What are the side effects of CYFENDUS?

Common side effects include Tenderness (injection-site), Pain (injection-site), Muscle aches, Tiredness, Arm motion limitation, Headache.

Last reviewed 2026-04-20 · How we verify

CYFENDUS

Emergent BioSolutions · FDA-approved active Biologic Quality 6/100

At a glance

Generic name	CYFENDUS
Sponsor	Emergent BioSolutions
Modality	Biologic
Therapeutic area	Infectious Disease
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

Tenderness (injection-site)
Pain (injection-site)
Muscle aches
Tiredness
Arm motion limitation
Headache
Warmth (injection-site)
Induration (injection-site)
Itching (injection-site)
Swelling (injection-site)
Erythema/redness (injection-site)

Key clinical trials

Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CYFENDUS CI brief — competitive landscape report
CYFENDUS updates RSS · CI watch RSS
Emergent BioSolutions portfolio CI